Диссертация (1141204), страница 19
Текст из файла (страница 19)
143–149.35. Blot S. Limiting the attributable mortality of nosocomial infection andmultidrug resistance in intensive care units // Clinical Microbiology andInfection. 2008. № 1 (14). C. 5–13.36. Blot S. et al. Does contemporary vancomycin dosing achievetherapeutic targets in a heterogeneous clinical cohort of critically ill patients?Data from the multinational DALI study // Critical Care.
2014.37. Bogard K.N. et al. Antibiotic dosing during sustained low-efficiencydialysis: Special considerations in adult critically ill patients // Critical CareMedicine. 2011. № 3 (39). C. 560–570.38. Bounthavong M. et al. Efficacy and safety of linezolid in methicillinresistant Staphylococcus aureus (MRSA) complicated skin and soft tissueinfection (cSSTI): a meta-analysis // Current medical research and opinion.
2010.№ 2 (26). C. 407–421.39. Brater D.C., Hall S.D. Disposition and Dose Requirements of Drugs inRenal Insufficiency 2008. 2763–2791 с.40. Bratzler D.W. et al. Clinical practice guidelines for antimicrobialprophylaxis in surgery // American Journal of Health-System Pharmacy. 2013.(14 #1). C. 73–156.41. Bresson J.
et al. Cefepime overdosage with neurotoxicity recovered byhigh-volume haemofiltration // Journal of Antimicrobial Chemotherapy. 2008. №4 (62). C. 849–850.42. Bruno R. et al. Evaluation of Bayesian estimation in comparison toNONMEM for population pharmacokinetic data analysis: application topefloxacin in intensive care unit patients // Journal of pharmacokinetics andbiopharmaceutics. 1992. № 6 (20). C. 653–669.43. Butterfield J. et al. Refining vancomycin protein binding estimates:identification of clinical factors that influence protein binding // Antimicrobialagents and chemotherapy. 2011.
C. AAC--01674.44. Cano E.L. et al. Incidence of nephrotoxicity and association with115vancomycin use in intensive care unit patients with pneumonia: retrospectiveanalysis of the IMPACT-HAP Database // Clinical therapeutics. 2012. № 1 (34).C. 149–157.45. Carricajo A. et al. Dosage adjustment of vancomycin in continuousinfusion in critically ill-patients 2010. 55–57 с.46. Case J. et al. Epidemiology of acute kidney injury in the intensive careunit // Critical Care Research and Practice. 2013.47. Cataldo M.A. et al.
Continuous versus intermittent infusion ofvancomycin for the treatment of Gram-positive infections: systematic review andmeta-analysis // Journal of antimicrobial chemotherapy. 2011. № 1 (67). C. 17–24.48. Chertow G.M. et al. Acute Kidney Injury, Mortality, Length of Stay,and Costs in Hospitalized Patients // J Am Soc Nephrol. 2005. № 11 (16). C.3365–3370.49. Cimino M.A. et al. Relationship of serum antibiotic concentrations tonephrotoxicity in cancer patients receiving concurrent aminoglycoside andvancomycin therapy // The American journal of medicine.
1987. № 6 (83). C.1091–1097.50. Claus B.O.M. et al. Augmented renal clearance is a common findingwith worse clinical outcome in critically ill patients receiving antimicrobialtherapy // Journal of critical care. 2013. № 5 (28). C. 695–700.51. Cockcroft D. W. et al. Prediction of creatinine clearance from serumcreatinine // Nephron. 1976. № 1 (16). C. 31–41.52. Craig W.A. Basic pharmacodynamics of antibacterials with clinicalapplications to the use of β-lactams, glycopeptides, and linezolid // InfectiousDisease Clinics. 2003. № 3 (17).
C. 479–501.53. Deresinski S., Trubiano J., Phillips E. Antimicrobial stewardship’s newweapon? A review of antibiotic allergy and pathways to ’de-labeling.” // ClinicalInfectious Diseases. 2016. № 10 (63). C. iii--iv.54. DeRyke C.A., Alexander D.P. Optimizing vancomycin dosing throughpharmacodynamic assessment targeting area under the concentration-timecurve/minimum inhibitory concentration // Hospital pharmacy. 2009. № 9 (44).C. 751–765.55. DeRyke C.A. Optimizing vancomycin dosing throughpharmacodynamic assessment targeting area under the concentration-timecurve/minimum inhibitory concentration // Hospital pharmacy. 2009. № 9 (44).C. 751–765.56. DiazGranados C.A.
et al. Comparison of mortality associated withvancomycin-resistant and vancomycin-susceptible enterococcal bloodstreaminfections: a meta-analysis // Clinical infectious diseases. 2005. № 3 (41). C. 327–333.57. Dodds T. J. et al. Linezolid versus vancomycin for MRSA skin and softtissue infections (systematic review and meta‐ analysis) // ANZ journal ofsurgery. 2009. № 9 (79). C. 629–635.11658. Drusano G.L. Antimicrobial pharmacodynamics: critical interactionsof’bug and drug’ // Nature Reviews Microbiology. 2004.
№ 4 (2). C. 289.59. Elbarbry F. Vancomycin Dosing and Monitoring: Critical Evaluation ofthe Current Practice // European journal of drug metabolism andpharmacokinetics. 2018. № 3 (43). C. 259–268.60. Falcone M., Russo A., Venditti M. Optimizing antibiotic therapy ofbacteremia and endocarditis due to staphylococci and enterococci: new insightsand evidence from the literature // Journal of Infection and Chemotherapy. 2015.№ 5 (21). C. 330–339.61. Farber B.F., Moellering R.C. Retrospective study of the toxicity ofpreparations of vancomycin from 1974 to 1981.
// Antimicrobial Agents andChemotherapy. 1983. № 1 (23). C. 138–141.62. Filsoufi F. et al. Epidemiology of deep sternal wound infection incardiac surgery // Journal of cardiothoracic and vascular anesthesia. 2009. № 4(23). C. 488–494.63. Fissell W.H. Antimicrobial Dosing in Acute Renal Replacement //Advances in Chronic Kidney Disease. 2013. № 1 (20). C. 85–93.64. for Medicinal Products for Human Use C., others European MedicinesAgency Committee for Medicinal Products for Human Use (CHMP) guideline onthe evaluation of anticancer medicinal products in man // London, UK: EuropeanMedicines Agency. 2006.65. Gatta M.M.F. et al.
Pharmacokinetic/pharmacodynamic analysis ofvancomycin in ICU patients // Intensive care medicine. 2007. № 2 (33). C. 279–285.66. Gelijns A.C. et al. Management practices and major infections aftercardiac surgery // Journal of the American College of Cardiology. 2014. № 4(64). C. 372–381.67. Geraci J. E. et al. Vancomycin in the treatment of staphylococcalendocarditis // Proceedings of the staff meetings. Mayo Clinic. 1960. (35).
C.316–326.68. Geraci J. E. et al. Some laboratory and clinical experiences with a newantibiotic, vancomycin // Proc. Staff, Meetings Mayo Clinic. 1956. № 21 (31). C.564–82.69. Gouvêa M. et al. Adherence to guidelines for surgical antibioticprophylaxis: a review // Brazilian Journal of Infectious Diseases. 2015.
№ 5 (19).C. 517–524.70. Greenstein A.J. et al. Risk factors for the development of fulminantClostridium difficile colitis // Surgery. 2008. № 5 (143). C. 623–629.71. Grill M.F., Maganti R.K. Neurotoxic effects associated with antibioticuse: management considerations // British journal of clinical pharmacology. 2011.№ 3 (72). C. 381–393.72. Gupta A., Biyani M., Khaira A. Vancomycin nephrotoxicity: myths andfacts // Neth J Med. 2011. № 9 (69). C. 379–383.73.
Haeseker M. et al. Evaluation of vancomycin prediction methods based117on estimated creatinine clearance or trough levels // Therapeutic drug monitoring.2016. № 1 (38). C. 120–126.74. Hal S.J. Van, Paterson D.L., Lodise T.P. Systematic review and metaanalysis of vancomycin-induced nephrotoxicity associated with dosing schedulesthat maintain troughs between 15 and 20 milligrams per liter // Antimicrobialagents and chemotherapy. 2013. № 2 (57).
C. 734–744.75. Hammett-Stabler C.A., Johns T. Laboratory guidelines for monitoringof antimicrobial drugs // Clinical chemistry. 1998. № 5 (44). C. 1129–1140.76. Harris D. et al. Epidemiology and outcomes of acute kidney injury incritically ill surgical patients // Journal of critical care. 2014. № 1 (30).
C. 102–106.77. Hassan M. El et al. Clinical pharmacists’ review of surgicalantimicrobial prophylaxis in a tertiary hospital in Abu Dhabi. // Internationaljournal of clinical pharmacy. 2015. № 1 (37). C. 18–22.78. Huh J.W. et al. A comparison of acute kidney injury classifications inpatients with severe sepsis and septic shock // The American journal of themedical sciences. 2012. № 5 (344). C.
350–356.79. Ishikawa S., Griesdale D.E.G., Lohser J. Acute kidney injury after lungresection surgery: Incidence and perioperative risk factors // Anesthesia andAnalgesia. 2012. № 6 (114). C. 1256–1262.80. Jeffres M.N. et al. Predictors of mortality for methicillin-resistantStaphylococcus aureus health-care--associated pneumonia: specific evaluation ofvancomycin pharmacokinetic indices // Chest. 2006. № 4 (130).
C. 947–955.81. Jelliffe R. Estimation of creatinine clearance in patients with unstablerenal function, without a urine specimen // American Journal of Nephrology.2002. № 4 (22). C. 320–324.82. Jiang W. et al. Morbidity and Mortality of Nosocomial Infection afterCardiovascular Surgery: A Report of 1606 Cases // Current Medical Science.2018. № 2 (38). C. 329–335.83.
Johnson A.P. Methicillin-resistant Staphylococcus aureus: theEuropean landscape // Journal of antimicrobial chemotherapy. 2011. № suppl_4(66). C. iv43--iv48.84. Jumah M.T. Bin et al.Pharmacokinetic/pharmacodynamicdeterminants of vancomycin efficacy in enterococcal bacteremia // Antimicrobialagents and chemotherapy. 2018. № 3 (62). C. e01602--17.85. Kahlberg A.
et al. How to best treat infectious complications of openand endovascular thoracic aortic repairs 2017. 95–102 с.86. Kalil A. C. et al. Linezolid versus vancomycin or teicoplanin fornosocomial pneumonia: a systematic review and meta-analysis // Critical caremedicine.
2010. № 9 (Т. 38. – №). C. 1802–1808.87. Kellum J.A. et al. Kidney disease: improving global outcomes(KDIGO) acute kidney injury work group. KDIGO clinical practice guideline foracute kidney injury // Kidney international supplements. 2012. № 1 (2). C. 1–138.88. Kenzaka T. M.M. Cefepime-induced encephalopathy // BMJ case118reports. (20).89. Khwaja A. et al. KDIGO clinical practice guidelines for acute kidneyinjury // Nephron Clinical Practice. 2012. № 4 (120). C. 179–184.90. Kiang T.K.L., Häfeli U.O., Ensom M.H.H. A comprehensive review onthe pharmacokinetics of antibiotics in interstitial fluid spaces in humans:Implications on dosing and clinical pharmacokinetic monitoring // ClinicalPharmacokinetics. 2014.91. Kirby W.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
